About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Oruka Therapeutics, Inc. (ORKA) Insider Trading
28 open-market trades reported since Jun 15, 2026: 0 purchases worth $0 and 28 sales worth $325.5M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Paul T. Quinlan | General Counsel | 0 | $0 | 5 | $7.44M |
| Joana Goncalves | Chief Medical Officer | 0 | $0 | 5 | $3.20M |
| Arjun Agarwal | President | 0 | $0 | 9 | $4.51M |
| Lawrence Otto Klein | CEO | 0 | $0 | 4 | $9.33M |
| Laura Lee Sandler | COO | 0 | $0 | 4 | $1.06M |
| Fairmount Funds Management LLC | Director | 0 | $0 | 1 | $300.0M |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Oct 20 | Paul T. QuinlanGeneral Counsel | ▼ SELL10b5-1 | $707K | |
| Oct 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $524K | |
| Oct 13 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $806K | |
| Oct 2 | Lawrence Otto KleinCEO | ▼ SELL10b5-1 | $2.09M | |
| Sep 21 | Paul T. QuinlanGeneral Counsel | ▼ SELL10b5-1 | $936K | |
| Sep 21 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $51K | |
| Sep 15 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $872K | |
| Sep 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $734K | |
| Sep 15 | Lawrence Otto KleinCEO | ▼ SELL | $235K | |
| Sep 15 | Paul T. QuinlanGeneral Counsel | ▼ SELL | $99K | |
| Sep 15 | Laura Lee SandlerCOO | ▼ SELL | $87K | |
| Sep 15 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $54K | |
| Sep 1 | Lawrence Otto KleinCEO | ▼ SELL10b5-1 | $6.89M | |
| Sep 1 | Laura Lee SandlerCOO | ▼ SELL10b5-1 | $459K | |
| Aug 17 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $783K | |
| Aug 14 | Paul T. QuinlanGeneral Counsel | ▼ SELL10b5-1 | $5.64M | |
| Aug 14 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $1.07M | |
| Jul 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $604K | |
| Jul 13 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $846K | |
| Jul 1 | Fairmount Funds Management LLCDirector | ▼ SELL | $300.0M | |
| Jul 1 | Laura Lee SandlerCOO | ▼ SELL10b5-1 | $472K | |
| Jun 22 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $128K | |
| Jun 15 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $660K | |
| Jun 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $551K | |
| Jun 15 | Lawrence Otto KleinCEO | ▼ SELL | $120K | |
| Jun 15 | Paul T. QuinlanGeneral Counsel | ▼ SELL | $51K | |
| Jun 15 | Laura Lee SandlerCOO | ▼ SELL | $42K | |
| Jun 15 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $28K |